Neuropeptide S attenuates neuropathological, neurochemical and behavioral changes induced by the NMDA receptor antagonist MK-801

Neuropharmacology

Volumn 58, Issue 1, 2010, Pages 166-172

  Okamura, Naoe ^a   Reinscheid, Rainer K ^a   Ohgake, Shintaro ^b   Iyo, Masaomi ^b   Hashimoto, Kenji ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Glutamate; Microdialysis; Neuropeptide; NMDA; Prepulse inhibition; Retrosplenial cortex; Schizophrenia

Indexed keywords

ACETYLCHOLINE; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE S;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BRAIN CORTEX; CELL VACUOLE; CONTROLLED STUDY; EXPERIMENTAL DESIGN; EXTRACELLULAR SPACE; FEMALE; MALE; MOUSE; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT;

ACOUSTIC STIMULATION; ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BRAIN; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; INHIBITION (PSYCHOLOGY); MALE; MICE; MICE, INBRED STRAINS; MICRODIALYSIS; NEUROPEPTIDES; NEUROTOXICITY SYNDROMES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 71549145280     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.06.027     Document Type: Article

References (40)

1. Auer R.N. Effect of age and sex on N-methyl-d-aspartate antagonist-induced neuronal necrosis in rats. Stroke 27 (1996) 743-746
2. Bakshi V.P., Swerdlow N.R., and Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther. 271 (1994) 787-794
3. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156 (2001) 234-258
4. Chumakov I., Blumenfeld M., Guerassimenko O., Cavarec L., Palicio M., Abderrahim H., et al. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13675-13680
5. Farber N.B., Foster J., Duhan N.L., and Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res. 21 (1996) 33-37
6. Farber N.B., Kim S.H., Dikranian K., Jiang X.P., and Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol. Psychiatry 7 (2002) 32-43
7. Farber N.B., Jiang X., Dikranian K., and Nemmers B. Muscimol prevents NMDA antagonist neurotoxicity by activating GABAA receptors in several brain regions. Brain Res. 993 (2003) 90-100
8. Fix A.S., Wozniak D.F., Truex L.L., McEwen M., Miller J.P., and Olney J.W. Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate/retrosplenial cortex. Brain Res. 696 (1995) 194-204
9. Furuya Y., Kagaya T., Ogura H., and Nishizawa Y. Competitive NMDA receptor antagonists disrupt prepulse inhibition without reduction of startle amplitude in a dopamine receptor-independent manner in mice. Eur. J. Pharmacol. 364 (1999) 133-140
10. Geyer M.A., and Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 1071-1079
11. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156 (2001) 117-154
12. Hashimoto K., Fujimura M., and Yamagami K. Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment. Life Sci. 66 (2000) 1071-1078
13. Hashimoto K., Okamura N., Shimizu E., and Iyo M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs. Curr. Med. Chem. - CNS Agents 4 (2004) 147-154
14. Heekeren K., Meincke U., Geyer M.A., and Gouzoulis-Mayfrank E. Attentional modulation of prepulse inhibition: a new startle paradigm. Neuropsychobiology 49 (2004) 88-93
15. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
16. Keene C.S., and Bucci D.J. Involvement of the retrosplenial cortex in processing multiple conditioned stimuli. Behav. Neurosci. 122 (2008) 651-658
17. Kim S.H., Price M.T., Olney J.W., and Farber N.B. Excessive cerebrocortical release of acetylcholine induced by NMDA antagonists is reduced by GABAergic and alpha2-adrenergic agonists. Mol. Psychiatry 4 (1999) 344-352
18. Lee F.J., Xue S., Pei L., Vukusic B., Chery N., Wang Y., et al. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111 (2002) 219-230
19. Leonard S.K., Dwyer J.M., Sukoff Rizzo S.J., Platt B., Logue S.F., Neal S.J., Malberg J.E., Beyer C.E., Schechter L.E., Rosenzweig-Lipson S., and Ring R.H. Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology (Berl) 197 (2008) 601-611
20. Lin S.H., Arai A.C., Wang Z., Nothacker H.P., and Civelli O. The carboxyl terminus of the prolactin-releasing peptide receptor interacts with PDZ domain proteins involved in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor clustering. Mol. Pharmacol. 60 (2001) 916-923
21. Lukoyanov N.V., and Lukoyanova E.A. Retrosplenial cortex lesions impair acquisition of active avoidance while sparing fear-based emotional memory. Behav. Brain Res. 173 (2006) 229-236
22. Maddock R.J. The retrosplenial cortex and emotion: new insights from functional neuroimaging of the human brain. Trends Neurosci. 22 (1999) 310-316
23. Okamura N., Hashimoto K., Shimizu E., Koike K., Ohgake S., Koizumi H., Kumakiri C., Komatsu N., and Iyo M. Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. Brain Res. 992 (2003) 114-119
24. Okamura N., Hashimoto K., Shimizu E., Kumakiri C., Komatsu N., and Iyo M. Adenosine A1 receptor agonists block the neuropathological changes in rat retrosplenial cortex after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 29 (2004) 544-550
25. Okamura N., Habay S.A., Zeng J., Chamberlin A.R., and Reinscheid R.K. Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor. J. Pharmacol. Exp. Ther. 325 (2008) 893-901
26. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry 52 (1995) 998-1007
27. Olney J.W., Labruyere J., and Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244 (1989) 1360-1362
28. Oranje B., Van Oel C.J., Gispen-De Wied C.C., Verbaten M.N., and Kahn R.S. Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia. J. Clin. Psychopharmacol. 22 (2002) 359-365
29. Reinscheid R.K., Xu Y.L., Okamura N., Zeng J., Chung S., Pai R., Wang Z., and Civelli O. Pharmacological characterization of human and murine neuropeptide S receptor variants. J. Pharmacol. Exp. Ther. 315 (2005) 1338-1345
30. Reinscheid R.K., Xu Y.L., and Civelli O. Neuropeptide S: a new player in the modulation of arousal and anxiety. Mol. Interv. 5 (2005) 42-46
31. Rizzi A., Vergura R., Marzola G., Ruzza C., Guerrini R., Salvadori S., Regoli D., and Calo G. Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br. J. Pharmacol. 154 (2008) 471-479
32. Sakaue M., Ago Y., Baba A., and Matsuda T. The 5-HT1A receptor agonist MKC-242 reverses isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl) 170 (2003) 73-79
33. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71 (2002) 877-892
34. Straub R.E., Jiang Y., MacLean C.J., Ma Y., Webb B.T., Myakishev M.V., et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 71 (2002) 337-348
35. Sutherland R.J., and Hoesing J.M. Posterior cingulate cortex and spatial memory: a microlimnology analysis. In: Vogt B.A., and Gabriel M. (Eds). Neurobiology of Cingulate Cortex and Limbic Thalamus (1993), Birkhauser, Boston 461-477
36. Tohmi M., Tsuda N., Mizuno M., Takei N., Frankland P.W., and Nawa H. Distinct influences of neonatal epidermal growth factor challenge on adult neurobehavioral traits in four mouse strains. Behav. Genet. 35 (2005) 615-629
37. Tomitaka S., Tomitaka M., Tolliver B.K., and Sharp F.R. Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex. Eur. J. Neurosci. 12 (2000) 1420-1430
38. Xu Y.L., Reinscheid R.K., Huitron-Resendiz S., Clark S.D., Wang Z., Lin S.H., Brucher F.A., Zeng J., Ly N.K., Henriksen S.J., de Lecea L., and Civelli O. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43 (2004) 487-497
39. Xu Y.L., Gall C.M., Jackson V.R., Civelli O., and Reinscheid R.K. Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S expressing neurons in the rat brain. J. Comp. Neurol. 500 (2007) 84-102
40. Zhang L., Shirayama Y., Iyo M., and Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 32 (2007) 2004-2010